BioXcel Therapeutics, Inc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings
BioXcel Therapeutics, Inc. (BTAI) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings of -$187.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Other Income
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings · last filed 2026-08-13
- BioXcel Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2026-06-30 was $16.00K.
- BioXcel Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2026-03-31 was -$203.00K.
- BioXcel Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2025-12-31 was -$685.00K.
- BioXcel Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2025-09-30 was $11.57M.
- BioXcel Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2025 was $9.03M.
- BioXcel Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2024 was -$602.00K.
- BioXcel Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2023 was -$438.00K.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 12 month |
|---|---|---|---|---|
| 2026-06-30 | $16.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$187.00K 10-Q · filed 2026-08-13 | -$872.00K derived: sum of 3 quarters · filed 2026-08-13 | $10.70M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$203.00K 10-Q · filed 2026-05-15 | -$888.00K derived: sum of 2 quarters · filed 2026-05-15 | $10.68M derived: sum of 3 quarters · filed 2026-05-15 | $10.26M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$685.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $10.89M derived: sum of 2 quarters · filed 2026-03-27 | $10.46M derived: sum of 3 quarters · filed 2026-08-13 | $9.03M 10-K · filed 2026-03-27 |
| 2025-09-30 | $11.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $11.15M derived: sum of 2 quarters · filed 2026-08-13 | $9.72M 10-Q · filed 2025-11-12 | $9.59M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$425.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$1.86M 10-Q · filed 2026-08-13 | -$1.99M derived: sum of 3 quarters · filed 2026-08-13 | -$2.11M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$1.43M 10-Q · filed 2026-05-15 | -$1.56M derived: sum of 2 quarters · filed 2026-05-15 | -$1.69M derived: sum of 3 quarters · filed 2026-05-15 | -$1.95M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | -$129.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | -$257.00K derived: sum of 2 quarters · filed 2026-03-27 | -$514.00K derived: sum of 3 quarters · filed 2026-03-27 | -$602.00K 10-K · filed 2026-03-27 |
| 2024-09-30 | -$128.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$385.00K derived: sum of 2 quarters · filed 2025-11-12 | -$473.00K 10-Q · filed 2025-11-12 | -$595.00K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$257.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$345.00K 10-Q · filed 2025-08-12 | -$467.00K derived: sum of 3 quarters · filed 2025-08-12 | -$466.00K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$88.00K 10-Q · filed 2025-05-12 | -$210.00K derived: sum of 2 quarters · filed 2025-05-12 | -$209.00K derived: sum of 3 quarters · filed 2025-05-12 | -$757.00K derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | -$122.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | -$121.00K derived: sum of 2 quarters · filed 2025-03-28 | -$669.00K derived: sum of 3 quarters · filed 2025-03-28 | -$438.00K 10-K · filed 2025-03-28 |
| 2023-09-30 | $1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$547.00K derived: sum of 2 quarters · filed 2024-11-14 | -$316.00K 10-Q · filed 2024-11-14 | |
| 2023-06-30 | -$548.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$317.00K 10-Q · filed 2024-08-06 | ||
| 2023-03-31 | $231.00K 10-Q · filed 2024-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |